<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02728778</url>
  </required_header>
  <id_info>
    <org_study_id>V4.11-BTX-BPD</org_study_id>
    <nct_id>NCT02728778</nct_id>
  </id_info>
  <brief_title>Botulinum Toxin A for Emotional Stabilization in Borderline Personality Disorder (BPD)</brief_title>
  <acronym>BTX-BPD</acronym>
  <official_title>Botulinum Toxin A for Emotional Stabilization in Borderline Personality Disorder (BPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hannover Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hannover Medical School</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the trial is to test whether a single application of botulinum toxin A&#xD;
      into the glabellar region will lead to emotional stabilization in borderline personality&#xD;
      disorder through paralysis of facial muscles/attenuation of negative emotions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Afferent feedback from facial muscles is believed to enhance emotional states (facial&#xD;
      feedback theory). The facial expression of negative emotions involves facial muscles of the&#xD;
      glabellar region. It has been shown that paralysis of facial muscles in the forehead using&#xD;
      botulinum toxin A leads to the improvement of depressive symptoms. It is believed that the&#xD;
      limited ability to express these emotions alleviates depressive symptoms. As Borderline&#xD;
      personality disorder is characterized by negative emotions expressed via facial muscles in&#xD;
      the forehead, it is hypothesized that BPD patients could profit from botulinum toxin&#xD;
      treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2016</start_date>
  <completion_date type="Actual">October 31, 2019</completion_date>
  <primary_completion_date type="Actual">April 30, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Zanarini Scale for Borderline personality disorder (ZAN-BPD)</measure>
    <time_frame>8 weeks</time_frame>
    <description>BPD severity measure expert rating</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Borderline symptom list (BSL-23)</measure>
    <time_frame>4, 8 and 16 weeks</time_frame>
    <description>BPD severity measure self rating</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montgomery-Asberg-Depression-Rating-Scale (MADRS)</measure>
    <time_frame>4, 8 and 16 weeks</time_frame>
    <description>depression severity measure expert rating</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck Depression Inventory (BDI)</measure>
    <time_frame>4, 8 and 16 weeks</time_frame>
    <description>depression severity measure self rating</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Borderline Personality Disorder</condition>
  <arm_group>
    <arm_group_label>Botulinum toxin A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single administration of incobotulinumtoxin A into the forehead (glabellar region); 34 U in five injection sites.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acupuncture</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will receive four facial acupuncture treatments every two weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>incobotulinumtoxin A</intervention_name>
    <description>Application of botulinum toxin A into the forehead</description>
    <arm_group_label>Botulinum toxin A</arm_group_label>
    <other_name>Botox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Acupuncture</intervention_name>
    <description>Application of acupuncture into the forehead</description>
    <arm_group_label>Acupuncture</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. female&#xD;
&#xD;
          2. 18-40 years&#xD;
&#xD;
          3. diagnosed BPD according to ICD-10 (F60.31) and SKID II&#xD;
&#xD;
          4. stable treatment&#xD;
&#xD;
          5. mastery of the German language&#xD;
&#xD;
          6. effective contraception&#xD;
&#xD;
          7. willingness to and acceptance of treatment with either botulinum toxin A or&#xD;
             acupuncture&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Comorbid disorders of all ICD-10 groups o F0,&#xD;
&#xD;
               -  F1 (with exception of F1x.1),&#xD;
&#xD;
               -  F2,&#xD;
&#xD;
               -  F3 (with exception of 32.0 and F33.0),&#xD;
&#xD;
               -  F7 and disorders essentially defining the clinical picture from sections&#xD;
&#xD;
               -  F4,&#xD;
&#xD;
               -  F5,&#xD;
&#xD;
               -  F6.&#xD;
&#xD;
          2. Contraindication for treatment with botulinum toxin A according to the IMP's SmPC&#xD;
             (e.g. myasthenia gravis, Lambert Eaton-syndrome or other impairments in neuromuscular&#xD;
             function)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>HCTC</last_name>
    <role>Study Chair</role>
    <affiliation>Hannover Clinical Trial Center HCTC GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hannover Medical School</name>
      <address>
        <city>Hannover</city>
        <state>Lower Saxony</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik Nord-Ochsenzoll</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 31, 2016</study_first_submitted>
  <study_first_submitted_qc>March 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2016</study_first_posted>
  <last_update_submitted>May 28, 2020</last_update_submitted>
  <last_update_submitted_qc>May 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hannover Medical School</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Tillmann Kr√ºger</investigator_full_name>
    <investigator_title>M.D., Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Personality Disorders</mesh_term>
    <mesh_term>Borderline Personality Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

